Brokerages Set Immuneering Corporation (NASDAQ:IMRX) PT at $13.25

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $13.25.

A number of equities research analysts recently commented on the stock. Mizuho lifted their price target on shares of Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Wednesday. Oppenheimer lowered their target price on Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 price target on shares of Immuneering in a research report on Wednesday. Finally, Chardan Capital reissued a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a report on Wednesday.

Immuneering Price Performance

Shares of NASDAQ IMRX traded down $0.21 during midday trading on Friday, reaching $2.56. The company's stock had a trading volume of 4,703,958 shares, compared to its average volume of 2,522,900. The stock has a market capitalization of $92.13 million, a P/E ratio of -1.31 and a beta of 0.01. The firm has a 50 day moving average price of $1.62 and a 200-day moving average price of $1.75. Immuneering has a 12-month low of $1.00 and a 12-month high of $3.83.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). On average, equities analysts predict that Immuneering will post -1.86 EPS for the current year.

Insider Buying and Selling at Immuneering

In related news, Director Thomas J. Schall purchased 40,485 shares of Immuneering stock in a transaction dated Tuesday, June 17th. The stock was bought at an average cost of $2.21 per share, for a total transaction of $89,471.85. Following the completion of the transaction, the director now owns 43,385 shares in the company, valued at $95,880.85. This trade represents a 1,396.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin J. Zeskind acquired 21,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 18th. The shares were bought at an average price of $2.39 per share, for a total transaction of $50,190.00. Following the completion of the purchase, the chief executive officer now owns 2,302,852 shares in the company, valued at $5,503,816.28. This trade represents a 0.92% increase in their position. The disclosure for this purchase can be found here. Insiders own 22.90% of the company's stock.

Institutional Investors Weigh In On Immuneering

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tang Capital Management LLC bought a new position in shares of Immuneering in the fourth quarter valued at approximately $27,000. Jane Street Group LLC purchased a new stake in Immuneering in the 1st quarter worth approximately $32,000. Marshall Wace LLP purchased a new stake in Immuneering in the 4th quarter worth approximately $47,000. First Manhattan CO. LLC. bought a new position in Immuneering in the 4th quarter valued at $71,000. Finally, XTX Topco Ltd grew its position in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after purchasing an additional 20,871 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.